Altimmune, Inc. - Common Stock (NQ:ALT)

2.670 -0.065 (-2.38%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Why Is Altimmune (ALT) Stock Down 67% Today? ↗

March 21, 2023

Altimmune (ALT) stock is losing value on Tuesday after the company released results from a Phase 2 clinical trial for obesity.

Via InvestorPlace

US Stocks Open Higher; Nasdaq Jumps Over 100 Points ↗

March 21, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.90% to 32,535.25 while the NASDAQ rose...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 21, 2023

Via Benzinga

Altimmune Stock Is Diving: What's Going On? ↗

March 21, 2023

Shares of clinical-stage biopharmaceutical company Altimmune Inc (NASDAQ: ALT) are trading lower Tuesday after the company announced results from an interim analysis of

Via Benzinga

Analyst Ratings for Altimmune ↗

March 09, 2023

Via Benzinga

Looking Into Altimmune's Return On Capital Employed ↗

March 03, 2023

Via Benzinga

Earnings Outlook For Altimmune ↗

February 27, 2023

Via Benzinga

4 Analysts Have This to Say About Altimmune ↗

January 20, 2023

Via Benzinga

Altimmune Touts Encouraging Data From Fatty Liver Disease Study ↗

December 20, 2022

Via Benzinga

Recent Selloff Is A 'Buying Opportunity' For This NASH Stock, Says Analyst ↗

September 16, 2022

Via Benzinga

Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week ↗

February 16, 2023

Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 16, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 13, 2023

Via Benzinga

7 Small-Cap Stocks with Big Growth Potential in 2023 ↗

January 10, 2023

Some of the greatest investment opportunities can be found in these top small-cap stocks to buy in the new year.

Via InvestorPlace

Lucid Group, Verona Pharma And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

December 20, 2022

U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Expert Ratings for Altimmune ↗

September 16, 2022

Analysts have provided the following ratings for Altimmune (NASDAQ:ALT) within the last quarter:

Via Benzinga

Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session ↗

December 21, 2022

Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical...

Via Benzinga

The 7 Hottest Biotech Stocks to Own in 2023 and Beyond ↗

December 18, 2022

Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year.

Via InvestorPlace

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

December 19, 2022

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

Via Benzinga

My 3 Top Biotech Stock Picks for 2023 ↗

November 22, 2022

Biotech stocks are set to shine in 2023.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022 ↗

December 01, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About Altimmune ↗

September 16, 2022

Over the past 3 months, 4 analysts have published their opinion on Altimmune (NASDAQ:ALT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Why NeuroBo Pharmaceuticals Is Trading Higher By Around 55%; Here Are 25 Stocks Moving Premarket ↗

September 15, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) rose 54.6% to $26.07 in pre-market trading after the company entered into an exclusive license agreement with Dong-A.

Via Benzinga

Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday ↗

September 26, 2022

Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.

Via Benzinga

Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session ↗

September 23, 2022

Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day...

Via Benzinga

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary ↗

September 14, 2022

Via Benzinga

Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday ↗

September 15, 2022

Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.

Via Benzinga

Dow, S&P 500 Turn Lower; Altimmune Shares Slide ↗

September 14, 2022

U.S. stocks pared gains toward the end of trading, with the Dow Jones dropping around 80 points on Wednesday.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 14, 2022

Via Benzinga

Why SciSparc Is Trading Higher By 68%, Here Are 48 Stocks Moving In Wednesday's Mid-Day Session ↗

September 14, 2022

Gainers Akerna Corp. (NASDAQ: KERN) shares rose 81.2% to $0.2355 after gaining 8% on Tuesday.

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.